Kevin Shenk,

Fiscal Assistant

Department: Fiscal & Logistics

Business Phone: (352) 273-6264

Business Email: kshenk@ufl.edu

About Kevin Shenk

Kevin Shenk has been working in the College of Pharmacy’s Fiscal Office as a Fiscal Representative located in the Shared Service Center since October 2016. While employed at UF he has completed the Pro 3 Series Fiscal Management Certification. Kevin handles all fiscal matters for the Department of Pharmaceutics. He also acts as the backup Fiscal Representative for the departments of Medicinal Chemistry (MC) and Pharmacotherapy & Translational Research (PTR).

Prior to his employment at UF, Kevin served honorably in the US Air Force for 6 years and continues to serve in the US Air Force Reserve. He also completed his Associate Degree in Business Administration and is continuing his schooling to obtain a Bachelor’s degree in Organizational Management.

Publications

2011

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.

Clinical cancer research : an official journal of the American Association for Cancer Research. 17(9):2734-43 [DOI] 10.1158/1078-0432.CCR-10-1950. [PMID] 21364033.

309 citations · PubMed · Publisher’s Site

2009

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.

Blood. 114(16):3439-47 [DOI] 10.1182/blood-2009-05-223677. [PMID] 19671918.

260 citations · PubMed · Publisher’s Site

2009

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Journal of medicinal chemistry. 52(9):3028-38 [DOI] 10.1021/jm801329v. [PMID] 19348473.

204 citations · PubMed · Publisher’s Site

2007

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Cancer research. 67(13):6383-91 [PMID] 17616698.

512 citations · PubMed

2007

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Blood. 110(9):3281-90 [PMID] 17591945.

565 citations · PubMed

2004

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.

Bioorganic & medicinal chemistry letters. 14(24):6017-21 [PMID] 15546720.

15 citations · PubMed

2004

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.

Bioorganic & medicinal chemistry letters. 14(2):549-52 [PMID] 14698201.

13 citations · PubMed

2004

Novel inhibitors of fatty acid oxidation as potential metabolic modulators.

Bioorganic & medicinal chemistry letters. 14(4):973-7 [PMID] 15013004.

5 citations · PubMed

2004

Structure-affinity relationships of 5′-aromatic ethers and 5′-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents.

Bioorganic & medicinal chemistry letters. 14(14):3793-7 [PMID] 15203164.

17 citations · PubMed

2000

Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists.

Bioorganic & medicinal chemistry letters. 10(11):1203-5 [PMID] 10866381.

12 citations · PubMed

Contact Details

Phones:

Business:: (352) 273-6264

Emails:

Business:: kshenk@ufl.edu

Addresses:

Business Mailing:: PO Box 100498
GAINESVILLE FL 32610
Business Street:: PO Box 100498
GAINESVILLE FL 32610